Skip to main content
. 2017 May 17;57(9):1148–1158. doi: 10.1002/jcph.920

Figure 1.

Figure 1

ADC and MMAE PK model schema after an intravenous infusion of brentuximab vedotin. ADC, antibody‐drug conjugate; DAR, drug‐antibody ratio; CL, clearance of ADC by proteolytic degradation; Q2 and Q3, ADC intercompartmental clearance; CLM, MMAE apparent clearance; MMAE, monomethyl auristatin E; Q5, MMAE apparent intercompartmental clearance.